SummaryBackgroundResults of studies evaluating the effect of viral eradication following direct‐acting antiviral (DDA) therapy on skeletal muscle mass of patients with chronic hepatitis C (CHC) are scarce.AimTo assess the components of sarcopenia (low muscle mass, low muscle strength and low physical performance) in a cohort of CHC individuals before and after DAA therapy.MethodsWe performed a longitudinal study of patients with CHC who underwent body composition assessment before (T0), and at 12 (T1) and 48 (T2) weeks after DDA therapy. Bioelectrical Impedance Analysis was used to assess skeletal mass muscle (SM) and phase angle (PhA). SM index (SMI) was calculated by dividing the SM by squared height. Muscle function was evaluated by hand grip strength (HGS) and timed up‐and‐go (TUG) test. Mixed‐effects linear regression models were fitted to SMI, HGS and physical performance and were used to test the effect of HCV eradication by DAA.Results62 outpatients (mean age, 58.6 ± 10.8 years; 58% with compensated cirrhosis) were included. Significant decreases in liver fibrosis markers and an increase of 0.20 and 0.22 kg/m2 in the SMI were observed at T1 and T2. Following DAA therapy, an increase of one unit of PhA was associated with a reduction of 0.38 min in TUG.ConclusionHCV eradication with DAA therapy was associated with a dynamic reduction of non‐invasive markers of liver fibrosis and increased muscle mass in 62 patients with CHC who had an undetectable HCV load at 12 weeks after completion of antiviral treatment.

中文翻译：

---

慢性丙型肝炎患者使用直接作用抗病毒药物根除病毒后骨骼肌质量增加：一项纵向研究

摘要背景评估直接作用抗病毒 (DDA) 治疗后病毒根除对慢性丙型肝炎 (CHC) 患者骨骼肌质量影响的研究结果很少。方法我们对 DDA 治疗前 (T0)、DDA 治疗后 12 (T1) 和 48 (T2) 周接受身体成分评估的 CHC 患者进行了纵向研究。生物电阻抗分析用于评估骨骼肌 (SM) 和相位角 (PhA)。 SM 指数 (SMI) 的计算方法是将 SM 除以高度的平方。通过握力（HGS）和定时起立（TUG）测试来评估肌肉功能。混合效应线性回归模型适合 SMI、HGS 和身体表现，并用于测试 DAA 根除 HCV 的效果。结果 纳入 62 名门诊患者（平均年龄，58.6 ± 10.8 岁；58% 患有代偿性肝硬化）。肝纤维化标志物显着降低，增加0.20和0.22 kg/m2在 T1 和 T2 时观察到 SMI 的变化。 DAA 治疗后，PhA 增加 1 个单位与 TUG 减少 0.38 分钟相关。 结论 在 62 名 CHC 患者中，DAA 治疗根除 HCV 与肝纤维化非侵入性标志物动态减少和肌肉质量增加相关完成抗病毒治疗后 12 周时 HCV 载量无法检测到。